Tags

Type your tag names separated by a space and hit enter

Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test.
Curr Med Res Opin. 2000; 16(1):14-20.CM

Abstract

The occurrence of intestinal bacterial overgrowth in patients with Crohn's Disease (CD) has been described and antimicrobial treatment has been shown to be effective in reversing this condition. However, the mechanisms underlying the efficacy of antimicrobial therapy are still only partially known. The aim of the present study was to evaluate the effect of a non-absorbable antibiotic (rifaximin) in comparison to placebo on bacterial overgrowth in patients with CD.

METHODS

Fourteen patients with inactive CD of the ileum and bacterial overgrowth, as assessed by the hydrogen breath test, were blindly allocated to receive rifaximin (1200 mg/day) or placebo t.i.d. for one week. A hydrogen breath test, and clinical and biochemical parameters were further performed 14 days and 30 days after starting treatment.

RESULTS

After 14 days, the hydrogen breath test proved to be negative in seven out of seven patients treated with rifaximin (p < 0.05), and in two out of seven in the placebo group (p = ns). After 30 days, the hydrogen breath test was positive in all patients of the rifaximin and placebo group, respectively. No changes in the CDAI score were documented in any patients.

CONCLUSIONS

Short-term administration of rifaximin is effective in the therapy of bacterial overgrowth in patients with inactive CD of the ileum, thus suggesting that the control of luminal bacterial growth could be useful in the management of these patients. However, since we observed a decline with time in this positive effect, further studies are needed to identify the most appropriate therapeutic strategies.

Authors+Show Affiliations

Istituto di Clinica Medica 2, Università La Sapienza, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16422030

Citation

Biancone, L, et al. "Effect of Rifaximin On Intestinal Bacterial Overgrowth in Crohn's Disease as Assessed By the H2-Glucose Breath Test." Current Medical Research and Opinion, vol. 16, no. 1, 2000, pp. 14-20.
Biancone L, Vernia P, Agostini D, et al. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. Curr Med Res Opin. 2000;16(1):14-20.
Biancone, L., Vernia, P., Agostini, D., Ferrieri, A., & Pallone, F. (2000). Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. Current Medical Research and Opinion, 16(1), 14-20.
Biancone L, et al. Effect of Rifaximin On Intestinal Bacterial Overgrowth in Crohn's Disease as Assessed By the H2-Glucose Breath Test. Curr Med Res Opin. 2000;16(1):14-20. PubMed PMID: 16422030.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. AU - Biancone,L, AU - Vernia,P, AU - Agostini,D, AU - Ferrieri,A, AU - Pallone,F, PY - 2006/1/21/pubmed PY - 2006/3/7/medline PY - 2006/1/21/entrez SP - 14 EP - 20 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 16 IS - 1 N2 - UNLABELLED: The occurrence of intestinal bacterial overgrowth in patients with Crohn's Disease (CD) has been described and antimicrobial treatment has been shown to be effective in reversing this condition. However, the mechanisms underlying the efficacy of antimicrobial therapy are still only partially known. The aim of the present study was to evaluate the effect of a non-absorbable antibiotic (rifaximin) in comparison to placebo on bacterial overgrowth in patients with CD. METHODS: Fourteen patients with inactive CD of the ileum and bacterial overgrowth, as assessed by the hydrogen breath test, were blindly allocated to receive rifaximin (1200 mg/day) or placebo t.i.d. for one week. A hydrogen breath test, and clinical and biochemical parameters were further performed 14 days and 30 days after starting treatment. RESULTS: After 14 days, the hydrogen breath test proved to be negative in seven out of seven patients treated with rifaximin (p < 0.05), and in two out of seven in the placebo group (p = ns). After 30 days, the hydrogen breath test was positive in all patients of the rifaximin and placebo group, respectively. No changes in the CDAI score were documented in any patients. CONCLUSIONS: Short-term administration of rifaximin is effective in the therapy of bacterial overgrowth in patients with inactive CD of the ileum, thus suggesting that the control of luminal bacterial growth could be useful in the management of these patients. However, since we observed a decline with time in this positive effect, further studies are needed to identify the most appropriate therapeutic strategies. SN - 0300-7995 UR - https://www.unboundmedicine.com/medline/citation/16422030/Effect_of_rifaximin_on_intestinal_bacterial_overgrowth_in_Crohn's_disease_as_assessed_by_the_H2_Glucose_Breath_Test_ L2 - http://www.tandfonline.com/doi/full/10.1185/0300799009117003 DB - PRIME DP - Unbound Medicine ER -